Aveanna's California Breakthrough Sparks a Growth Re-Rate
Momentum That Finally Matches the Message
Aveanna Healthcare (AVAH) has been telling a patient, rate-driven growth story for four years. In Q2 2026, the market finally started believing it. Revenue rose 13.7% to $670M, adjusted EBITDA grew 8% to $95.4M, and the company raised its full-year guidance to revenue >$2.68B and EBITDA >$365M. The stock responded with a +111.6% move over the last 90 days, and the whole-history trend line now shows a sharp up-14w:+112% segment breaking out of a long drawdown.
The energy on the call was unmistakable. CEO Jeffrey Shaner didn't just present results—he declared victory on a decade-long fight. The Family First Homecare integration is on track, the MCO payer strategy now covers 64% of PDS volumes (up from 60% at Q1), and home health episodic mix hit 81%. But the headline is California.
After 4 years of dedicated advocacy… the 2027 California budget includes a significant investment in pediatric private duty nursing rates effective January 1, 2027.
Just three months earlier, on the Q4 2025 call, Shaner had said the chance of a California PDN rate increase making the budget was "less than 10% or 15%." The reversal is a direct payoff of the company's M&A activity and geographic-diversification thesis—and it resets the long-term growth algorithm: PDS organic growth guidance rises from 3–5% to 5–6%, and home health & hospice from 5–7% to a striking 8–10%.
Wage Pass-Through: The Real Operating Lever
Management was explicit that the rate increased will be passed through to caregivers, not pocketed. CFO Matthew Buckhalter described the playbook: start pushing wages out in Q4 ahead of the January 1 effective date, fill authorized hours, then "unlock the unnecessary days that were being spent in the hospital." This is the same model that worked in Georgia—where a similar rate reset three years ago cleared out a children's hospital's hallways within months. California is materially larger, so the runway is meaningful.
The financials confirm the operating improvements. Gross margin held at 32.6% while revenue reaccelerated—exactly the "rate-to-wage pass-through" equilibrium Shaner described. Operating income grew 34% yoy even as the company invested ahead of volume. And leverage is finally below 4x after the credit-rating upgrades and a 75bp term-loan repricing.
The Bull Case Now Rests on Execution
The prior-quarter worries about the home-health moratorium and OBBA headwinds have largely faded from the narrative. Instead, the call leaned into the demand side: 18.5% episodic volume growth, a 20th preferred payer agreement in Medical Solutions, and a 95k unique-patient month. The risk is that the stock has already priced in a lot—but the company's own Private Duty nursing momentum (the sector keyword is at its highest level in two years) suggests the theme is broadening.
"We have come a long way as an industry," Shaner said of the CMS home-health rate settlement, and the same could be said of Aveanna itself. The next test is whether California's rate can deliver the promised census unlock—and whether the company can keep absorbing wage inflation while holding gross margins. “We expect full year revenue to be greater than $2.68 billion and adjusted EBITDA greater than $365 million.” — Matthew Buckhalter, Chief Financial Officer · 2026-08-13 That guidance, raised purely on core performance (Family First was already baked in), gives the bulls a concrete bar.
For investors, the setup is simple: the rate-reimbursement flywheel is finally spinning in the largest pediatric home-nursing state, and the company has the balance sheet (net leverage headed toward sub-3x) to keep acquiring tuck-ins in the same mold. “Just months ago, a California increase was "less than 10% or 15%."” — Jeffrey S. Shaner, Chief Executive Officer · 2026-03-19 That flip—from improbable to announced—is why this quarter feels like an inflection rather than just another beat.